New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.

35 , 36 The ZODIAC and the ZEAL, two randomized, double-blind Phase III trials, compared vandetanib 100 mg plus docetaxel or pemetrexed to docetaxel or pemetrexed alone, respectively: while the first combination showed an improvement in median PFS with a positive trend, but not statistically significant, in OS, 37 the combination with pemetrexed didn’t meet the first endpoint, the PFS. 38 In a Phase III trial (Zactima Efficiacy when Studied versus Tarceva [ZEST]), vandetanib versus erlotinib was evaluated in 1240 pretreated patients with advanced NSCLC; vandetani

also in 11,005 other papers